张高明;张国明;郭绪晓;杨莉;马小波;韩洪波;

• 1:沭阳县人民医院
• 2:山东中医药大学附属医院检验科

摘要(Abstract)：

目的研究2型糖尿病肾脏疾病(T2DKD)病人血清中血清淀粉样蛋白A-低密度脂蛋白(serum amyloid A-low-density lipoprotein complex,SAA-LDL)水平变化及其与氧化型低密度脂蛋白(oxidized low density lipoprotein,ox LDL)的相关关系。方法按尿微量清蛋白/尿肌酐比(Urine Albumin-to-Creatinine Ratio,UACR)水平将260例T2DM病人分3组:单纯糖尿病(SD组,n=80),早期糖尿病肾脏疾病(ED组,n=86)和临床糖尿病肾脏疾病(CD组,n=94),另选体检中心体检健康者作为对照(NC组,80例),分别测定各组血清空腹血糖(FGP),糖化血红蛋白(Hb A1c),超敏C反应蛋白(hs CRP),ox LDL,SAA-LDL,低密度脂蛋白质胆固醇(LDL-C)等相关指标并进行相关分析。结果 SD组,ED组,CD组血清SAA-LDL和ox LDL水平较对照组升高并随清蛋白尿水平升高而增加。SAA-LDL与hs-CRP,ox LDL正相关(r=0.871,P<0.05;r=0.762,P<0.05)。结论 T2DKD患者SAA-LDL水平明显升高,SAA-LDL与hs-CRP,ox LDL正相关,SAA-LDL可能促进T2DKD发生,发展。

关键词(KeyWords)： 2型糖尿病;肾脏疾病;淀粉样蛋白A-低密度脂蛋白复合物;氧化低密度脂蛋白;尿清蛋白;尿蛋白

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 张高明;张国明;郭绪晓;杨莉;马小波;韩洪波;

DOI: 10.13799/j.cnki.mdjyxyxb.2015.05.006

参考文献(References)：

• [1]Nation Kidney Foundation.KDOQITM clinical practice guideline and clinicalpractice recommendation for diabetes and chronic kidney disease[J].Am J Kidney Dis,2007,49(Suppl 2):S1-S180.
• [2]张国明,胡礼仪,于琦,等.2型糖尿病肾病血清氧化型低密度脂蛋白与尿清蛋白排泄率关系的研究[J].现代检验医学杂志,2010,25(2):90-91,94.
• [3]Lehmann R,Schleiher ED.Molecular mechanism of diabetic nephropathy[J].Clin Chim Acta,2000,297(1):135.
• [4]Mashiba S,Ogasawara K,Wada Y,et al.Development of blood examination method of serum amylid A and LDL complex,and clinical application to prediction of cardiovascular event[J].Rinsho Byori,2004,52:67-74.
• [5]Ogasaware K,Mashiba S,Wada Y,et al.A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease[J].Atherosclerosis,2004,174:349-356.
• [6]张瑞英,许小进,富路,等.血清淀粉样蛋白A和血清淀粉样蛋白A-低密度脂蛋白复合物与冠心病的临床研究[J].中华老年心脑血管病杂志,2010,12(2):123-126.
• [7]Kotani K;Koibuchi H;Yamada T,et al.The effects of lifestyle modification on a new oxidized low-density lipoprotein marker,serum amyloid A-LDL,in subjects with primary lipid disorder[J].Clinica chimica acta;2009,409(1-2):67-69.
• [8]Kotani K;Satoh N;Kato Y,et al.A novel oxidized low-density lipoprotein marker,serum amyloid A-LDL,is associated with obesity and the metabolic syndrome[J].Atherosclerosis.2009,204(2):526-531.
• [9]Kotani K,Satoh N,Yamada T.Bezafibrate and serum amyloid A-low-density lipoprotein complex in patients with type 2 diabetes mellitus and hypertriglyceridemia[J].European journal of internal medicine.2010 21(2):e10.
• [10]Kotani K1,Asahara-Satoh N,Kato Y,et al.Remnant-like particle cholesterol and serum amyloid A-low-density lipoprotein levels in obese subjects with metabolic syndrome[J].Journal of clinical lipidology.2011 5(5):395-400.
• [11]Kotani K,Satoh-Asahara N,Kato Y,Serum amyloid A lowdensity lipoprotein levels and smoking status in obese Japanese patients[J].J Int Med Res.2011;39(5):1917-1922.
• [12]Kotani K,Yamada T,Miyamoto M,Ishibashi S,Influence of atorvastatin on serum amyloid A-low density lipoprotein complex in hypercholesterolemic patients[J].Pharmacol Rep.2012;64(1):212-216.